Top Story

Tarextumab granted orphan drug designation for pancreatic, small cell lung cancers

January 29, 2015

The FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small cell lung cancer, the drug’s manufacturer announced today.

Preclinical studies have demonstrated that tarextumab (OMP-59R5, OncoMed) — a fully monoclonal antibody that targets Notch2 and Notch3 receptors — has anti-cancer stem cell activity and affects pericytes that impact the stromal and tumor microenvironment.

In the Journals

Teledermoscopy accepted by patients, effective in monitoring atypical nevi

January 29, 2015
Patients were receptive to the use of teledermoscopy, which was effective for short-term monitoring of clinically atypical nevi, according to recently published study…
FDA News

FDA designates Neutrolin as QIDP

January 29, 2015
The FDA has designated a novel formulation as a qualified infectious disease product, for the prevention of catheter-related bloodstream infections for oncology…
In the Journals

Artificial hybrid likely required for treating giant cell tumor of bone with zoledronic acid

January 29, 2015
In a recently published study, researchers determined that to effectively treat giant cell tumors of bone with zoledronic acid, a hybrid including artificial bone would…
FDA News

FDA expands approval of Imbruvica to treat Waldenström's macroglobulinemia

January 29, 2015
The FDA today announced the expanded approval of ibrutinib for the treatment of Waldenström’s macroglobulinemia, a rare form of non-Hodgkin’s lymphoma…
More News Headlines »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan
morganatic-roan